Importance Progression-free survival (PFS) has become a commonly used outcome to
assess the efficacy of new cancer drugs. However, it is not clear if delay in progression leads …

Tumor growth requires induction of an angiogenic program, and targeting of this program
with antiangiogenic drugs shows an impact on tumor progression. However, although they …

The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …

Background: Many patients participate in cancer trials to access new therapies. The extent to
which new treatments produce clinical benefit for trial participants is unclear. Purpose: To …

Tumour progression requires the activation of a tumour and stromal cell‐driven angiogenic
programme, and the targeting of this process demonstrates an impact on tumour growth and …

Purpose Based on improvements of progression-free survival (PFS), new agents for
metastatic renal cell carcinoma (mRCC) have been approved. It is assumed that one of the …

Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-
derived growth factor receptor-α, and c-kit. Phase I studies demonstrated 5 mg twice daily as …

Renal Cell Carcinomas (RCCs) are tumors derived from the epithelial components of the
nephron and constitutes 80-85% of all primary renal neoplasms. The worldwide incidence of …

The focus of this paper is the requirement that the use of live animals in experiments and in
vivo assays should never be allowed if those uses involve severe suffering. This …

Background Renal Cell Carcinoma (RCC) is the most common type of kidney cancer (85%).
75% of the RCC cases involve conventional clear cell RCC (ccRCC). Approximately, 39% of …